Biomarker Analysis in Metastatic Colorectal Cancer Treated With Cetuximab
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- To explore biomarkers predictive of clinical response to cetuximab-based treatment in metastatic colorectal cancer using the Prometheus Platform
研究概览
简要总结
Prometheus's Onco dX assay platform provides technological breakthrough for immunoassay by obtaining a level of sensitivity down to single tumor cells without compromising specificity. This allows assessment of multiple TKI treatment targets, their activation status, as well as down stream signaling proteins using very tiny amount of tissue that can be obtained by FNA or CTCs.
We planned this study to explore biomarkers predictive of clinical response to cetuximab-based treatment in metastatic colorectal cancer using the Prometheus Platform. We will also elucidate signal transduction pathway attributable to cetuximab resistance, monitor changes in the RTK activation status during cetuximab treatment using circulating tumor cells and analyze correlation between the quantity of circulating tumor cells and treatment response to cetuximab.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically confirmed metastatic colorectal cancer
- •Cetuximab-based chemotherapy (monotherapy, combination therapy with cytotoxic chemotherapy such as FOLFOX, XELOX, irinotecan, FOLFIRI, XELIRI, first-line, second-line or third-line are all eligible)
- •Age > 18 years.
- •ECOG Performance Status of 0-2
- •Adequate bone marrow, liver and renal function
- •Signed and dated informed consent before the start of specific protocol procedures.
- •FNA will be performed in patients with feasible biopsy site; ascites or pleural fluid will be collected in metastatic CRC patients with ascites or pleural effusion
排除标准
- •Active clinically serious infections (> grade 2 CTCAE version 3.0)
- •Patients with evidence or history of bleeding diathesis
- •Radiotherapy during study or within 4 weeks of start of study drug.
- •Prior exposure to the study drug.
- •Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
结局指标
主要结局
To explore biomarkers predictive of clinical response to cetuximab-based treatment in metastatic colorectal cancer using the Prometheus Platform
时间窗: at Screening (Day - 21 ~ 0 ), at 4 weeks and average 6months(end of treatment)
A. To analyze expression and activation status of receptor tyrosine kinases in signal transduction pathways in FNA samples and circulating tumor cells B. To identify negative predictive markers to cetuximab
次要结局
- 1. RTK activation status during cetuximab treatment using circulating tumor cells(at Screening (Day - 21 ~ 0 ), at 4 weeks and average 6months(end of treatment))
- 2. signal transduction pathway attributable to cetuximab resistance(at Screening (Day - 21 ~ 0 ), at 4 weeks and EOT (end of treatment))
- 3. To analyze correlation between the quantity of circulating tumor cells and treatment response to cetuximab(at Screening (Day - 21 ~ 0 ), at 4 weeks and average 6months (end of treatment))
研究者
Joon Oh Park
MD, PhD
Samsung Medical Center